1. Home
  2. Research and Funding
  3. Current Funding Opportunities
  4. Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R41/R42)

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R41/R42)

The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active R41/R42 Small Business Technology Transfer (STTR) Grant awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.

Funding Opportunity Details


Deborah K. Hoshizaki, PhD.

Key Dates


May 26, 2017

June 26, 2017, by 5:00 PM local time of applicant organization.

All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

No late applications will be accepted for this Funding Opportunity Announcement

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.